Co-immunization with two recombinant Eimeria tenella lines expressing immunoprotective antigens of E. maxima elicits enhanced protection against E. maxima infection
Live anticoccidial vaccines have been a tremendous success for disease prevention. The establishment of the reverse genetic manipulation platform has enabled the development of Eimeria parasites, the live anticoccidial vaccine strains, as vaccine vectors. In our previous study, recombinant E. tenella expressing a single immunodominant antigen of E. maxima (Et-EmIMP1) was able to protect chickens against challenge infection with E. maxima. This promising result encouraged us to further explore strategies to improve the protection efficacy of recombinant Eimeria and develop it as a vaccine vector.
We constructed a novel recombinant Eimeria line expressing apical membrane antigen 1 of E. maxima (Et-EmAMA1) and then immunized chickens with Et-EmAMA1 and/or Et-EmIMP1. We found that the E. maxima soluble antigen-specific cell-mediated immunity was much stronger in the birds that were co-immunized with Et-EmAMA1 and Et-EmIMP1 than in those that were immunized with Et-EmAMA1 or Et-EmIMP1 alone. The oocyst production after E. maxima infection was significantly reduced in the recombinant Eimeria-immunized birds compared with the wild-type-immunized and naïve birds. The oocyst production in the birds co-immunized with Et-EmAMA1 and Et-EmIMP1 was consistently the lowest among the treatment groups after E. maxima infection.
These results demonstrated that Eimeria is an effective vaccine vector that can carry and deliver heterologous Eimeria antigens to the host immune system and trigger specific immune responses. Our results also suggested that increasing the number of recombinant Eimeria lines is an effective approach to enhance protective immunity against infections with heterologous pathogens.
KeywordsRecombinant Eimeria Vaccine vector Apical membrane antigen 1 Immune mapped protein 1 Immune responses
immune mapped protein 1
apical membrane antigen 1
surface antigen 13
Eimeria maxima antigen
peripheral blood mononuclear cells
open reading frame
restriction enzyme-mediated integration
indirect immunofluorescent assay
specific pathogen free
enzyme-linked immunospot assay
The genus Eimeria causes coccidiosis in a wide range of domestic and wild animals [1, 2, 3, 4, 5]. Eimeria parasites with good immunogenicity have been developed as virulent or attenuated live coccidiosis vaccines that have achieved great successes in practice, especially in chickens and turkeys [6, 7]. With the rapid development of bioinformatics and the establishment of the genetic manipulation platform in apicomplexan parasites [8, 9, 10, 11], Eimeria parasites have shown great potential for development as vaccine delivery vectors [12, 13, 14, 15, 16]. Currently, Eimeria vectors carrying immunoprotective or immunodominant antigen(s) of heterologous Eimeria species to elicit cross-protective immunities against the parental and heterologous Eimeria species is a novel strategy to develop next-generation coccidiosis vaccines. Using this strategy, one or several Eimeria species of the vaccine formulation can be removed, which can reduce the adverse pathological reaction caused by vaccination. Thus, the cost will be reduced and the safety will be improved for the novel coccidiosis vaccines [12, 16].
In our previous study, immune mapped protein 1 of E. maxima (EmIMP1) expressed by recombinant E. tenella was shown to be recognized by the host immune system and triggered a moderate EmIMP1-specific immune response . Vaccination with this recombinant E. tenella line provided solid protection against E. tenella infection and partial protection against E. maxima infection in chickens . These results indicate that Eimeria may be an effective antigen(s) delivery system among species with similar modes of infection and immunity. It is essential to explore strategies to improve the protection elicited by recombinant Eimeria against infections with heterologous species.
We hypothesized that the protective immunity could be strengthened by increasing the number of recombinant Eimeria lines expressing heterologous pathogens’ immunodominant antigens. To investigate this hypothesis, we constructed another recombinant E. tenella line expressing the recognized immunoprotective antigen, apical membrane antigen 1 of E. maxima (EmAMA1) , and then measured its immunogenicity in this study. Moreover, we assessed the improvement of the protection of chickens after co-immunization with double recombinant Eimeria lines, i.e. a recombinant Eimeria line expressing EmAMA1 (Et-EmAMA1) constructed in this study and Et-EmIMP1 .
Parasites and animals
Eimeria tenella (XJ strain), E. maxima (BJ strain) and recombinant E. tenella expressing EmIMP1 (Et-EmIMP1)  were used in this project and maintained by propagating these parasites in coccidian-free, 2–5-week-old Arbor Acres (AA) broilers, which were purchased from Beijing Arbor Acres Poultry Breeding Co., Ltd. (Beijing, China). The procedures for collection, purification and sporulation were carried out as previously described .
One-week- or three-week-old specific pathogen-free (SPF) chickens (White Leghorn) were purchased from Merial Animal Health Co., Ltd. (Beijing, China) and were fed a pathogen-free diet and water ad libitum.
Recombinant Eimeria construction
Et-EmAMA1 selection based on EYFP expression
% EYFP expression
Drug + FACSa
Drug + FACS
ELISA and ELISPOT
Five groups of three-week-old SPF chickens (6 chickens/group) were either left naïve (Ctrl) or were immunized by infection with 200 sporulated wild-type E. tenella (WT), Et-EmIMP1, Et-EmAMA1 and an equivalent mixture of Et-EmIMP1 and Et-EmAMA1 oocysts. Secondary immunization was administered at 2-week intervals with 5000 oocysts as the immunization dosage for each bird. The E. maxima oocysts antigen (EmAg)-specific humoral and cellular immune responses were analyzed by ELISA and enzyme-linked immunospot assay (ELISPOT), respectively. EmAg was obtained from purified sporulated oocysts as previously described . EmAg (5 μg/ml) was coated onto the individual wells of the plate followed by a reaction with the serum (diluted in 1:100) collected from the birds at 2 weeks after primary and secondary (booster) immunization. The HRP-conjugated goat anti-chicken IgY Fc fragment (diluted in 1:5000; Bethyl Laboratories, Inc., Montgomery, TX, USA) was used as the secondary antibody. The optical density was measured by a microplate reader (Model 60; Bio-Rad, Hercules, CA, USA) at 450 nm.
Eimeria maxima parasite antigen-specific cellular immune responses revealed by IFN-γ secreting cells present in peripheral blood mononuclear cells (PBMCs) were evaluated byELISPOT at 2 weeks after secondary immunization following the established protocols [21, 23]. Briefly, 1 × 106 PBMCs from the 3 randomly selected birds of each group were separately stimulated with 10 μl of PBS, 10 μl of E. maxima oocysts antigen (EmAg, 10 μg/ml) or 10 μl Phorbol-12-myristate-13-acetate (PMA) plus ionomycin (10 ng/ml PMA plus 5 μg/ml ionomycin). IFN-γ-secreting lymphocytes were detected after 24 h of stimulation.
Vaccination and challenge infection
Groups of inbred SPF chickens (18 chickens/group) were either left naïve (Ctrl) or were immunized by infection with 200 sporulated wild-type E. tenella (WT) oocysts, 200 sporulated Et-EmIMP1 oocysts, 200 sporulated Et-EmAMA1 oocysts and 100 sporulated Et-EmIMP1 together with 100 sporulated Et-EmAMA1 oocysts at one week of age. New chopped straw litter was spread over the bottom of the cages to a depth of 5 cm. The chickens were housed under the same temperature and humidity conditions and fed a coccidian-free diet and water ad libitum. Six chickens from each group were separately removed to new cages (which contained a metal mesh which separated the chickens from feces) at 14, 21 and 42 dpi. The chickens were orally challenged with E. maxima (50 oocysts/bird) after each removal. The fecal samples were collected every day from day 5 to 12 after each challenge infection. The total number of oocysts in the feces was evaluated using a McMaster egg counting chamber after each challenge infection.
GraphPad Prism v.6.01 (GraphPad Software) was used for statistical analysis. Differences in experimental treatments were tested using Duncan’s Multiple Range Test following ANOVA with significance reported at P ≤ 0.05.
Construction of a recombinant E. tenella line expressing E. maxima AMA1 (Et-EmAMA1)
In the last decade, a technical platform for the construction and selection of recombinant Eimeria parasites has been successfully developed [9, 20]. In this study, the transfection plasmid, pSDEP2AAMA1S (Fig. 1a) was constructed based on the previously constructed pSDEP2AIMP1S plasmid . This new plasmid contains a single expression cassette in which the selected marker gene and EmAMA1 gene tagged with the flag epitope were linked by a P2A sequence, which mediates the cleavage of the dual flanking proteins . The expression cassette was controlled by the EtSAG13 (E. tenella surface antigen 13) promoter (Fig. 1a) . Eimeria tenella sporozoites were transfected with the linearized pSDEP2AAMA1S plasmid and then inoculated into the cloacal opening of chicks. The percentage of reporter positive recombinant Eimeria (Fig. 1b) in the 1st generation progeny was 32.3% (Table 1). The positive population of recombinant Eimeria tended to be stable after 3 generations under selection pressure (Table 1). In addition, the recombinant population remained stable without selection pressure (Table 1).
Next, we conducted serial experiments to identify the expression of exogenous EmAMA1 in the recombinant parasites. We confirmed the insertion of the EmAMA1 gene into the recombinant Eimeria genome by PCR using specific primers (Fig. 1c). The expression of EmAMA1 in the sporulated oocyst stage was demonstrated by Western botting using flag-tag specific-antibodies (Fig. 1d). We found that exogenous EmAMA1 was mainly expressed on the cell surface and the apex of the recombinant Eimeria sporozoites (Fig. 1e). These data showed that we obtained a recombinant Eimeria population stably expressing exogenous EmAMA1.
Et-EmAMA1 elicited E. maxima antigen specific cellular immunity
Co-immunization with Et-EmAMA1 and Et-EmIMP1 enhanced the protective efficacy against E. maxima infection
In this study, we successfully obtained a recombinant E. tenella line expressing heterologous EmAMA1 and tested its immunogenicity. We found that both Et-EmAMA1 and Et-EmIMP1  could protect chickens against heterologous E. maxima infection, and the protection could be enhanced by co-immunization with double recombinant Eimeria lines. In addition to previous findings, these results suggested that Eimeria is an effective vaccine vector that can carry and deliver Eimeria and other pathogens’ antigens to the host immune system and trigger specific immune responses [12, 13, 14, 15]. Our results also suggest that increasing the number of recombinant Eimeria lines may be an effective approach to strengthen the protective immunity against infections with heterologous pathogens. This is of great significance for developing next-generation coccidiosis vaccines that can simplify formulations of recombinant vaccines for animals and humans.
Our results show that recombinant Eimeria efficiently elicited heterologous antigen specific antibody production and cell-mediated immunity. The cell-mediated immunity rather than antibody production was improved when co-immunized with double recombinant Eimeria lines (Fig. 2) suggest that the enhanced protection by co-immunization is related to cellular immunity. Parallel experiments demonstrated that the secretion or cell surface display of EmAMA1 in recombinant E. tenella elicited EmAMA1 specific-antibody production. Multiple immunizations with recombinant Eimeria could partly protect the chickens against a moderate dose (300 oocysts/bird) of E. maxima infection . The reduced oocyst production after challenge infection in recombinant Eimeria immunized birds may be related to the reduced serum IL-10 level . Using EmIMP1 in recombinant protein or EmAMA1 in DNA formulations has been reported to achieve a reduction of approximately 45% in parasite production in small-scale vaccination trials [26, 27]. The reduction in oocyst production was 30–90% using E. tenella or E. acervulina antigens in recombinant protein, DNA or live-vector formulations with or without cytokines as adjuvants [27, 28]. Moreover, the protection against E. tenella, E. necatrix, E. maxima or E. acervulina infection was also reported to be enhanced using multivalent epitope DNA vaccines from multiple antigens compared to a single antigen [29, 30, 31, 32, 33, 34]. Although those subunit or recombinant vaccines achieved promising successes in the laboratory and are much safer and less expensive than live anticoccidial vaccines, no large-scale trials have been reported . One explanation may be the lack of automation systems for mass immunization and that chickens experience more stress with intramuscular injection of recombinant protein and DNA vaccines than with oral immunization with live anticoccidial vaccines [35, 36, 37]. Another explanation could be that the achieved protection through recombinant protein and DNA vaccines can only be detected after one or two booster immunizations, whereas a single oral immunization with live oocysts can elicit long-term protective immunity [6, 38].
To date, no matter the form of antigen delivery, i.e. recombinant protein, DNA or live vector including Eimeria, antigens can elicit complete protection as effective as live anticoccidial vaccines in the field. Our present results show promise for improving immune protection by recombinant Eimeria by increasing the number or category of heterologous antigens. Solutions include but are not limited to: (i) using advanced biotechnological tools to discover new immunodominant antigen(s) of Eimeria, such as IMP1 ; (ii) improving the heterologous antigen expression level by using a stronger promoter or increasing the gene copy number, etc. ; (iii) co-expressing multiple immunodominant antigens mediated by P2A in one recombinant Eimeria line or by double or multiple expression cassette [24, 39]; (iv) optimizing the antigens’ location in recombinant Eimeria for efficient recognition by host immune system ; and (v) fusion expression of heterologous antigens with cytokine(s) or other molecular adjuvants [21, 25, 40].
Recombinant E. tenella expressing an immunodominant antigen of E. maxima (EmAMA1) elicited partial protection against E. maxima infection in chickens, and the protection was improved by co-immunization with two recombinant Eimeria lines (Et-EmIMP1 and Et-EmAMA1). Our results provide a good basis for further development of next-generations coccidiosis vaccines and possess great significance for developing other recombinant vaccines for animals and humans.
XT, XS and SC conceived and designed this study and analyzed the data. XT carried out the experiments and drafted the manuscript. CW, LL, DH, SZ, CD and JS contributed to conducting animal experiments and the statistical analysis. XL, XS and SC supervised the study implementation and revised the manuscript. All authors read and approved the final manuscript.
This work was supported by the Agricultural Science and Technology Innovation Program of China (ASTIP-IAS15), the National Natural Science Foundation of China (31472180) and the China Postdoctoral Science Foundation (2018M641566).
Ethics approval and consent to participate
Animal experiments were approved by the Beijing Administration Committee of Laboratory Animals. All animal experiments were performed in strict accordance with the China Agricultural University Institutional Animal Care and Use Committee guidelines (CAU20160629-1) and followed the International Guiding Principles for Biomedical Research Involving Animals.
Consent for publication
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.